MX2007007033A - Estreptococus del grupo b. - Google Patents

Estreptococus del grupo b.

Info

Publication number
MX2007007033A
MX2007007033A MX2007007033A MX2007007033A MX2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A MX 2007007033 A MX2007007033 A MX 2007007033A
Authority
MX
Mexico
Prior art keywords
streptococcus
group
vaccines
antibiotics
polypeptides
Prior art date
Application number
MX2007007033A
Other languages
English (en)
Spanish (es)
Inventor
Vega Masignani
Herve Tettelin
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of MX2007007033A publication Critical patent/MX2007007033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007007033A 2004-12-22 2005-12-21 Estreptococus del grupo b. MX2007007033A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63894304P 2004-12-22 2004-12-22
US64043804P 2004-12-30 2004-12-30
PCT/US2005/046491 WO2006069200A2 (en) 2004-12-22 2005-12-21 Group b streptococcus

Publications (1)

Publication Number Publication Date
MX2007007033A true MX2007007033A (es) 2007-08-03

Family

ID=36602309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007033A MX2007007033A (es) 2004-12-22 2005-12-21 Estreptococus del grupo b.

Country Status (8)

Country Link
US (1) US20090104218A1 (enExample)
EP (1) EP1828231A2 (enExample)
JP (1) JP2008525033A (enExample)
AU (1) AU2005319174A1 (enExample)
CA (1) CA2591510A1 (enExample)
IL (1) IL183830A0 (enExample)
MX (1) MX2007007033A (enExample)
WO (1) WO2006069200A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
US6812021B1 (en) 1998-12-22 2004-11-02 Microscience Limited Genes and proteins and their use
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
EP1801235A1 (en) * 2005-12-20 2007-06-27 Institut Pasteur Rapid detection of the "high virulent" ST-17 clone of Group B streptococcus
EP2029623A2 (en) * 2006-06-19 2009-03-04 Mutabilis SA Identification of genes implicated in the virulence of streptococcus agalactiae
EP2063911A2 (en) * 2006-07-26 2009-06-03 Novartis Ag Immunogenic compositions for gram positive bacteria
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
EP2135877A1 (en) * 2008-06-19 2009-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Marker of steptococcus anginosus/Streptococcus constellatus (Moac) and uses thereof
US8147849B2 (en) 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
WO2011008548A1 (en) 2009-06-29 2011-01-20 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
MX344120B (es) 2011-01-20 2016-12-06 Genocea Biosciences Inc Vacunas y composiciones contra streptococcus pneumoniae.
EP2682401A4 (en) * 2011-02-02 2015-06-03 Microbial Chem Res Found FOR OBTAINING THE BLOOD-BRAIN-DISABLED MEDICAMENT OUTPUT MATERIAL, PEPTIDE THEREOF AND USE THEREOF
EP2557424A1 (en) 2011-08-11 2013-02-13 InGen Biosciences Method for diagnosing Streptococcus, Enterococcus and Pepstostreptococcus genera infections
WO2013124473A1 (en) * 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
MX2014011652A (es) * 2012-03-30 2014-10-24 Du Pont Enzimas utiles para la produccion de peracidos.
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
US20160145591A1 (en) * 2013-07-16 2016-05-26 Universite De Lausanne Bacterial lysins and uses thereof
JP2017523985A (ja) * 2014-08-05 2017-08-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原用担体分子
PL3411389T3 (pl) 2016-02-04 2021-10-25 Genovis Ab Nowe proteazy streptokokowe
US11028159B2 (en) 2017-05-02 2021-06-08 Venomyx, Inc. Composition and methods for treating snake envenomation
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
PL239045B1 (pl) * 2018-01-09 2021-11-02 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Epitop specyficzny dla zakaźnych Streptococcus agalactiae oraz sposób wykrywania zakażenia pacjenta szczepem Streptococcus agalactiae
GB2597566B (en) * 2018-06-13 2023-02-01 Gen Probe Inc Compositions and methods for detecting group B streptococcus nucleic acid
BR122021012517A2 (pt) 2018-08-06 2021-08-10 Medikine, Inc. Ligante il-2rgamac, composto compreendendo referido ligante, composição farmacêutica e uso do referido ligante
AU2020380296A1 (en) 2019-11-05 2022-06-16 Medikine Inc. IL-2RβγC binding compounds
IL293553A (en) * 2019-12-06 2022-08-01 Theratechnologies Inc Conjugated compounds that bind sortilin, preparations and uses thereof for the treatment of cancer
JP2023514128A (ja) 2020-02-03 2023-04-05 メディカイン、インコーポレイテッド ＩＬ－７Ｒαγｃ結合化合物
WO2021163584A1 (en) * 2020-02-12 2021-08-19 The Broad Institute, Inc. Field deployable crispr-cas diagnostics and methods of use thereof
US11639523B2 (en) 2020-03-23 2023-05-02 The Broad Institute, Inc. Type V CRISPR-Cas systems and use thereof
WO2022026534A1 (en) * 2020-07-28 2022-02-03 Kansas State University Research Foundation Sars-cov-2 immunogenic compositions and methods for protecting against sars-cov-2 clinical signs
MX2023005180A (es) * 2020-11-04 2023-05-15 Medikine Inc Compuestos de union a il-2r\03b2?c y usos de estos.
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2025017062A1 (en) * 2023-07-18 2025-01-23 Intervet International B.V. New type of streptococcus agalactiae serotype ia bacterium and vaccines thereof
TW202542195A (zh) * 2024-01-08 2025-11-01 美商得納利醫療公司 用於調節Ｔａｕ表現之組成物及方法
WO2025250877A1 (en) * 2024-05-31 2025-12-04 Saliogen Therapeutics, Inc. Mobile genetic elements from myotis myotis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
GB9808327D0 (en) * 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
CA2337102A1 (en) * 1998-07-27 2000-02-10 Richard William Falla Le Page Nucleic acids and proteins from group b streptococcus
GB9921125D0 (en) * 1999-09-07 1999-11-10 Microbial Technics Limited Proteins
US7939087B2 (en) * 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
FR2824074A1 (fr) * 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
EP2314604A3 (en) * 2002-10-15 2011-05-25 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Also Published As

Publication number Publication date
IL183830A0 (en) 2007-10-31
US20090104218A1 (en) 2009-04-23
JP2008525033A (ja) 2008-07-17
WO2006069200A2 (en) 2006-06-29
AU2005319174A1 (en) 2006-06-29
WO2006069200A3 (en) 2007-03-01
CA2591510A1 (en) 2006-06-29
EP1828231A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
MX2007007033A (es) Estreptococus del grupo b.
MY154904A (en) Neuropilin antagonists
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
EA201301072A1 (ru) Антитела против il-23p19 и их применение
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EP4435100A3 (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
NZ598176A (en) Disintegrin variants and pharmaceutical uses thereof
IL184288A0 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
WO2008002672A3 (en) Targets for use in diagnosis, prognosis and therapy of cancer
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
WO2009050277A3 (en) Edta resistant s100a12 complexes (erac)
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2007117763A3 (en) Methods and compositions for targeting relt
WO2008054595A3 (en) Drug controlled molecular tags
WO2003093298A3 (en) Immunogenic peptides
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
BRPI0818715A2 (pt) proteína m de streptococcus, fragmentos imunogênicos, ácidos nucléicos e métodos de uso
GB0604938D0 (en) Proteins, nucleic acids and medicaments
TW200640932A (en) Clopidogrel base suitable for pharmaceutical formulation and preparation thereof
ATE541855T1 (de) Weitere kristalline formen von rostafuroxin
WO2006089209A3 (en) Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: J. CRAIG VENTER INSTITUTE, INC.

FA Abandonment or withdrawal